Name: Working Capital Turnover

Definition: Working capital turnover shows how efficiently the company uses its short-term resources — like cash, inventory, and receivables — to generate sales. Higher turnover means the company squeezes more sales from its working capital. Lower turnover may indicate inefficient inventory, slow collections, or too much short-term capital tied up unnecessarily.

Interpretation:
• In '2021', CRSP's working capital turnover was 0.40, showing how efficiently working capital is deployed. Industry average for Biotechnology: Biological Products (No Diagnostic Substances) in '2021' stood at 0.37.
• In '2022', CRSP's working capital turnover was 0.00, showing how efficiently working capital is deployed. The decline from '2021' may indicate some operational or financial challenges. Industry average for Biotechnology: Biological Products (No Diagnostic Substances) in '2022' stood at 0.31. Industry average declined by 0.05 from previous year.
• In '2023', CRSP's working capital turnover was 0.21, showing how efficiently working capital is deployed. The increase since '2022' reflects strengthening financial performance. Industry average for Biotechnology: Biological Products (No Diagnostic Substances) in '2023' stood at 0.26. Industry average declined by 0.05 from previous year.
• In '2024', CRSP's working capital turnover was 0.02, showing how efficiently working capital is deployed. The decline from '2023' may indicate some operational or financial challenges. Industry average for Biotechnology: Biological Products (No Diagnostic Substances) in '2024' stood at 0.32. Industry average increased by 0.05 compared to previous year.
Overall, CRSP's working capital turnover has been volatile but showed a downward trend over the past 4 years.

Formula: Working Capital Turnover = Net Sales / Working Capital

Good Range: Ranges 5-20 depending on business.